Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma

Kaminski, M S; Zasadny, K R; Francis, I R; Fenner, M C; Ross, C W; Milik, A W; Estes, J; Tuck, M; Regan, D; Fisher, S; Glenn, S D; Wahl, R L

doi:10.1200/jco.1996.14.7.1974

Cited by 400Radiopharmaceutical Chemistry and ApplicationsLymphoma Diagnosis and TreatmentMonoclonal and Polyclonal Antibodies Research

Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma

Kaminski, M S, Zasadny, K R, Francis, I R, Fenner, M C, Ross, C W, Milik, A W, Estes, J, Tuck, M +4 more·1996·Journal of Clinical Oncology

DOI 10.1200/jco.1996.14.7.1974

Open this paper in CoChat — free account

Abstract

PURPOSE: The CD20 B-lymphocyte surface antigen expressed by B-cell lymphomas is an attractive target for radioimmunotherapy, treatment using radiolabeled antibodies. We conducted a phase I dose-escalation trial to assess the toxicity, tumor targeting, and efficacy of nonmyeloablative doses of an anti-CD20 monoclonal antibody (anti-B1) labeled with iodine-131 (131I) in 34 patients with B-cell lymphoma who had failed chemotherapy. PATIENTS AND METHODS: Patients were first given tracelabeled doses of 131I-labeled anti-B1 (15 to 20 mg, 5 mCi) to assess radiolabeled antibody biodistribution, and then a radioimmunotherapeutic dose (15 to 20 mg) labeled with a quantity of 131I that would deliver a specified centigray dose of whole-body radiation predicted by the tracer dose. Whole-body radiation doses were escalated from 25 to 85 cGy in sequential groups of patients in 10-cGy increments. To evaluate if radiolabeled antibody biodistribution could be optimized, initial patients were given one or two additional tracer doses on successive weeks, each dose preceded by an infusion of 135 mg of unlabeled anti-B1 one week and 685 mg the next. The unlabeled antibody dose resulting in the most optimal tracer biodistribution was also given before the radioimmunotherapeutic dose. Later patients were given a single tracer dose and radioimmunotherapeutic dose preceded by infusion of 685 mg of unlabeled anti-B1. RESULTS: Treatment was well tolerated. Hematologic toxicity was dose-limiting, and 75 cGy was established as the maximally tolerated whole-body radiation dose. Twenty-eight patients received radioimmunotherapeutic doses of 34 to 161 mCi, resulting in complete remission in 14 patients and a partial response in eight. All 13 patients with low-grade lymphoma responded, and 10 achieved a complete remission. Six of eight patients with transformed lymphoma responded. Thirteen of 19 patients whose disease was resistant to their last course of chemotherapy and all patients with chemotherapy-sensitive disease responded. The median duration of complete remission exceeds 16.5 months. Six patients remain in complete remission 16 to 31 months after treatment. CONCLUSION: Nonmyeloablative radioimmunotherapy with 131I-anti-B1 is associated with a high rate of durable remissions in patients with B-cell lymphoma refractory to chemotherapy.

Integrity signals

Registry

Crossref · 10.1200/jco.1996.14.7.1974

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The clinical trials leading to approval of anti-CD20 radioimmunotherapies intentionally excluded patients with bone marrow involvement with tumor of .25%.
“The clinical trials leading to the approval of anti-CD20 radioimmunotherapies intentionally excluded patients with bone marrow involvement with tumor of . 25% ( 92 ).”
From Normal-Tissue Tolerance to Radiopharmaceutical Therapies, the Knowns and the Unknowns (2021) · cites this paper as [92]
Whole-body absorbed dose has been used effectively as a surrogate for marrow dosimetry in patients receiving 131I-tositumomab, with an MTD of 75 cGy as a single administration in heavily pretreated patients without major marrow involvement with tumor.
“and in patients receiving 131 I-tositumomab (MTD 5 75 cGy, single administration in heavily pretreated patients without major marrow involvement with tumor) ( 92 , 93 ).”
From Normal-Tissue Tolerance to Radiopharmaceutical Therapies, the Knowns and the Unknowns (2021) · cites this paper as [92]

Sorted by citations

IDEC-C2B8 (Rituximab) Anti-CD20 Monoclonal Antibody Therapy in Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma
Maloney, D. G., Grillo-López, A. J., White, C. A., Bodkin, D., Schilder, R. J., Neidhart, J. A., Janakiraman, N., Foon, K. A., Liles, T.-M., Dallaire, B. K., et al. (1997) · Blood · doi:10.1182/blood.v90.6.2188 · Cited by 1,732 · see citing works
Improving the efficacy of antibody-based cancer therapies
Carter, P. M. (2001) · Nature reviews. Cancer · doi:10.1038/35101072 · Cited by 833 · see citing works
Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells
Till, B. G., Jensen, M. C., Wang, J., Chen, E., Wood, B. L., Greisman, H. A., Qian, X., James, S. E., Raubitschek, A. A., Forman, S. J., et al. (2008) · Blood · doi:10.1182/blood-2007-12-128843 · Cited by 721 · see citing works
131 I-Tositumomab Therapy as Initial Treatment for Follicular Lymphoma
Kaminski, M. S., Tuck, M. K., Estes, J. M., Kolstad, A., Ross, C. W., Zasadny, K. R., Regan, D. D., Kison, P. V., Fisher, S., Kroll, S., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa041511 · Cited by 715 · see citing works
Self-citation
IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma.
Maloney, D. G., Grillo-López, A. J., Bodkin, D., White, C. A., Liles, T. M., Royston, I., Varns, C., Rosenberg, J., & Levy, R. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.10.3266 · Cited by 633 · see citing works
Pivotal Study of Iodine I 131 Tositumomab for Chemotherapy-Refractory Low-Grade or Transformed Low-Grade B-Cell Non-Hodgkin’s Lymphomas
Kaminski, M. S., Zelenetz, A. D., Press, O. W., Saleh, M. N., Leonard, J. P., Fehrenbacher, L., Lister, T. A., Stagg, R., Tidmarsh, G. F., Kroll, S., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.19.3918 · Cited by 585 · see citing works
Self-citation
Apoptosis of Malignant Human B Cells by Ligation of CD20 With Monoclonal Antibodies
Shan, D., Ledbetter, J. A., & Press, O. W. (1998) · Blood · doi:10.1182/blood.v91.5.1644 · Cited by 572 · see citing works
Phase I/II Trial of IDEC-Y2B8 Radioimmunotherapy for Treatment of Relapsed or Refractory CD20+B-Cell Non-Hodgkin's Lymphoma
Witzig, T. E., White, C. A., Wiseman, G. A., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.12.3793 · Cited by 541 · see citing works
Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation
Colombat, P. (2001) · Blood · doi:10.1182/blood.v97.1.101 · Cited by 527 · see citing works
Radioimmunotherapy with iodine 131I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience
Kaminski, M. S., Estes, J., Zasadny, K. R., Francis, I. R., Ross, C. W., Tuck, M., Regan, D., Fisher, S., Gutierrez, J., Kroll, S., et al. (2000) · Blood · doi:10.1182/blood.v96.4.1259 · Cited by 525 · see citing works
Demonstration of accuracy and clinical versatility of mutual information for automatic multimodality image fusion using affine and thin-plate spline warped geometric deformations
Meyer, C. R., Boes, J. L., Kim, B., Bland, P. H., Zasadny, K. R., Kison, P. V., Koral, K. F., Frey, K. A., & Wahl, R. L. (1997) · Medical Image Analysis · doi:10.1016/s1361-8415(97)85010-4 · Cited by 460 · see citing works
“The patient was treated therapeutically with 100 mCi of 131 I labeled antibodies for non-Hodgkin's lymphoma 90 h prior to SPECT imaging (Kaminski et al., 1993, 1996).”
MethodSelf-citation
Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells
Shan, D., Ledbetter, J. A., & Press, O. W. (2000) · Cancer Immunology Immunotherapy · doi:10.1007/s002620050016 · Cited by 386 · see citing works
Multicenter Phase II Study of Iodine-131 Tositumomab for Chemotherapy-Relapsed/Refractory Low-Grade and Transformed Low-Grade B-Cell Non-Hodgkin’s Lymphomas
Vose, J. M., Wahl, R. L., Saleh, M. N., Rohatiner, A. Z. S., Knox, S. J., Radford, J. A., Zelenetz, A. D., Tidmarsh, G. F., Stagg, R., & Kaminski, M. S. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.6.1316 · Cited by 360 · see citing works
Self-citation
Long-Term Follow-Up of Autologous Bone Marrow Transplantation in Patients With Relapsed Follicular Lymphoma
Freedman, A. S., Neuberg, D. S., Mauch, P., et al. (1999) · Blood · doi:10.1182/blood.v94.10.3325.422k13_3325_3333 · Cited by 351 · see citing works
Therapeutic cancer targeting peptides
Aina, O. H., Sroka, T. C., Chen, M., & Lam, K. S. (2002) · Biopolymers · doi:10.1002/bip.10257 · Cited by 313 · see citing works
Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescue.
Liu, S. Y., Eary, J. F., Petersdorf, S. H., Martin, P. J., Maloney, D. G., Appelbaum, F. R., Matthews, D. C., Bush, S. A., Durack, L. D., Fisher, D. R., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.10.3270 · Cited by 285 · see citing works
Clinical trials of antibody therapy
Glennie, M. J., & Johnson, P. (2000) · Immunology Today · doi:10.1016/s0167-5699(00)01669-8 · Cited by 290 · see citing works
Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention
Jazirehi, A. R., & Bonavida, B. (2005) · Oncogene · doi:10.1038/sj.onc.1208349 · Cited by 275 · see citing works
“Thus, to enhance the efficacy of immunotherapy, toxins and radionuclides have been conjugated to B1 and 1F5 mAbs (Press et al., 1987; Press et al., 1993, 1995; Kaminski et al., 1993, 1996).”
Background
Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial
Wiseman, G. A., Gordon, L. I., Multani, P. S., Witzig, T. E., SPIES, S. M., Bartlett, N. L., Schilder, R. J., Murray, J. L., Saleh, M. N., Allen, R. S., et al. (2002) · Blood · doi:10.1182/blood.v99.12.4336 · Cited by 265 · see citing works
Efficacy and Safety of Tositumomab and Iodine-131 Tositumomab (Bexxar) in B-Cell Lymphoma, Progressive After Rituximab
Horning, S. J., Younes, A., Jain, V. K., Kroll, S., Lucas, J. B., Podoloff, D. A., & Goris, M. L. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2005.07.040 · Cited by 259 · see citing works
Mouse CD20 expression and function
Uchida, J. (2003) · International Immunology · doi:10.1093/intimm/dxh009 · Cited by 244 · see citing works
Tositumomab and Iodine-131 Tositumomab Produces Durable Complete Remissions in a Subset of Heavily Pretreated Patients With Low-Grade and Transformed Non-Hodgkin’s Lymphomas
Fisher, R. I., Kaminski, M. S., Wahl, R. L., Knox, S. J., Zelenetz, A. D., Vose, J. M., Leonard, J. P., Kroll, S., Goldsmith, S. J., & Coleman, M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2004.00.9217 · Cited by 240 · see citing works
Self-citation
Phase I/II 90 Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma
Wiseman, G. A., White, C. A., Stabin, M., Dunn, W. L., Erwin, W. D., Dahlbom, M. L., Raubitschek, A. A., Karvelis, K. C., Schultheiss, T. E., Witzig, T. E., et al. (2000) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s002590000276 · Cited by 234 · see citing works
Gemcitabine Treatment in Pretreated Cutaneous T-Cell Lymphoma: Experience in 44 Patients
Zinzani, P. L., Baliva, G., Magagnoli, M., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.13.2603 · Cited by 226 · see citing works
Monoclonal Antibody Therapy for Cancer
von Mehren, M., Adams, G. P., & Weiner, L. M. (2003) · Annual Review of Medicine · doi:10.1146/annurev.med.54.101601.152442 · Cited by 191 · see citing works
Prognosis of follicular lymphoma: a predictive model based on a retrospective analysis of 987 cases. Intergruppo Italiano Linfomi.
Federico, M., Vitolo, U., Zinzani, P. L., et al. (2000) · PubMed · Cited by 183 · see citing works
Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin™ radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma
Wiseman, G. A., White, C. A., Sparks, R. B., et al. (2001) · Critical Reviews in Oncology/Hematology · doi:10.1016/s1040-8428(01)00107-x · Cited by 183 · see citing works
“The volatile nature of iodine also poses an inhalation hazard to staff and dehalogenation of I with accumulation of free iodine in the thyroid poses a risk of hypothyroidism, though this can be reduced if an adequate thyroid blocking regime is followed [3].”
Background
Radioimmunotherapy of non-Hodgkin lymphomas
Cheson, B. D. (2002) · Blood · doi:10.1182/blood-2002-06-1793 · Cited by 182 · see citing works
A monoclonal antibody recognizing human cancers with amplification/overexpression of the human epidermal growth factor receptor
Jungbluth, A. A., Stockert, E., Huang, H., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.232686499 · Cited by 175 · see citing works
IDEC‐C2B8 anti‐CD20 (Rituximab) immunotherapy in patients with low‐grade non‐Hodgkin's lymphoma and lymphoproliferative disorders: evaluation of response on 48 patients
Nguyen, D. T., AMESS, J. A. L., Doughty, H. A., Hendry, L., & Diamond, L. W. (1999) · European Journal Of Haematology · doi:10.1111/j.1600-0609.1999.tb01725.x · Cited by 162 · see citing works
Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab
Bennett, J. M. (2005) · Blood · doi:10.1182/blood-2004-12-4690 · Cited by 160 · see citing works
“Median number of prior therapies (range) 3 (1-13) 0 (0-0)”
Background
Clinical radionuclide therapy dosimetry: the quest for the “Holy Gray”
Brans, B. T., Bodei, L., Giammarile, F., Lindén, O., Luster, M., Oyen, W. J. G., & Tennvall, J. (2007) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-006-0338-5 · Cited by 158 · see citing works
IDEC-C2B8 (Rituximab) Anti-CD20 Monoclonal Antibody Therapy in Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma
Maloney, D. G., Grillo-López, A. J., White, C. A., et al. (1997) · Blood · doi:10.1182/blood.v90.6.2188.2188_2188_2195 · Cited by 154 · see citing works
Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) in relapsed B-cell lymphoma
Tobinai, K., Kobayashi, Y., Narabayashi, M., Ogura, M., Kagami, Y., MORISHIMA, Y., Ohtsu, T., Igarashi, T., Sasaki, Y., Kinoshita, T., et al. (1998) · Annals of Oncology · doi:10.1023/a:1008265313133 · Cited by 150 · see citing works
The Radioisotope Contributes Significantly to the Activity of Radioimmunotherapy
Davis, T. A., Kaminski, M. S., Leonard, J. P., Hsu, F. J., Wilkinson, M. J., Zelenetz, A. D., Wahl, R. L., Kroll, S., Coleman, M., Goris, M. L., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0756 · Cited by 152 · see citing works
“The sites did quality control testing for immunoreactivity and purity as described previously (16).”
BackgroundSelf-citation
Accurate dosimetry in 131I radionuclide therapy using patient-specific, 3-dimensional methods for SPECT reconstruction and absorbed dose calculation.
Dewaraja, Y. K., Wilderman, S. J., Ljungberg, M. H., et al. (2005) · PubMed · Cited by 143 · see citing works
Self-citation
Cancer Immunotherapy
Dillman, R. O. (2011) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2010.0902 · Cited by 156 · see citing works
Factors affecting toxicity, response and progression-free survival in relapsed patients with indolent B-cell lymphoma and mantle cell lymphoma treated with rituximab: a Japanese phase II study
Igarashi, T., Kobayashi, Y., Ogura, M., Kinoshita, T., Ohtsu, T., Sasaki, Y., MORISHIMA, Y., Murate, T., Kasai, M., Uike, N., et al. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf155 · Cited by 139 · see citing works
“Among the various new treatment modalities against indolent B-cell lymphoma and MCL, monoclonal antibody (mAb) therapy has been considered one of the most promising treatment strategies [8–10].”
Tumor Immunology
Sogn, J. A. (1998) · Immunity · doi:10.1016/s1074-7613(00)80641-x · Cited by 141 · see citing works
Pretargeted Radioimmunotherapy (PRIT™) for Treatment of Non-Hodgkin's Lymphoma (NHL): Initial Phase I/II Study Results
Weiden, P. L., Breitz, H. B., Press, O. W., et al. (2000) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2000.15.15 · Cited by 138 · see citing works
“Treatment other than chemotherapy: Bl is RIT according to Kaminski, et al (reference 16), Transplant refers to high dose chemoradiotherapy followed by stem cell infusion. studied.”
Cancer Radioimmunotherapy
Sharkey, R. M., & Goldenberg, D. M. (2011) · Immunotherapy · doi:10.2217/imt.10.114 · Cited by 136 · see citing works
Antibody-Targeted Immunotherapy for Treatment of Malignancy
White, C. A., Weaver, R. L., & Grillo-López, A. J. (2001) · Annual Review of Medicine · doi:10.1146/annurev.med.52.1.125 · Cited by 130 · see citing works
Prolonged Single-Agent Versus Combination Chemotherapy in Indolent Follicular Lymphomas: A Study of the Cancer and Leukemia Group B
Peterson, B. A., Petroni, G. R., Frizzera, G., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2003.05.128 · Cited by 125 · see citing works
Patient-specific, 3-dimensional dosimetry in non-Hodgkin's lymphoma patients treated with 131I-anti-B1 antibody: assessment of tumor dose-response.
Sgouros, G., Squeri, S., Ballangrud, Å., Kolbert, K. S., Teitcher, J. B., Panageas, K. S., Finn, R. D., Divgi, C. R., Larson, S. M., & Zelenetz, A. D. (2003) · PubMed · Cited by 119 · see citing works
Pharmacokinetics, dosimetry, and initial therapeutic results with 131I- and (111)In-/90Y-labeled humanized LL2 anti-CD22 monoclonal antibody in patients with relapsed, refractory non-Hodgkin's lymphoma.
Juweid, M. E., Stadtmauer, E. A., Hajjar, G., et al. (1999) · PubMed · Cited by 119 · see citing works
Treatment of Refractory Hodgkin's Lymphoma Patients With an Iodine-131–Labeled Murine Anti-CD30 Monoclonal Antibody
Schnell, R., Dietlein, M., Staak, J. O., Borchmann, P., Schomaecker, K., Fischer, T. H., Eschner, W., Hansen, H. P., Morschhauser, F., Schicha, H., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.09.098 · Cited by 116 · see citing works
Radiolabeled Anti-CD20 Monoclonal Antibodies for the Treatment of B-Cell Lymphoma
Dillman, R. O. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.02.126 · Cited by 115 · see citing works
Phase I radioimmunotherapy of metastatic renal cell carcinoma with 131I-labeled chimeric monoclonal antibody G250.
Steffens, M. G., Boerman, O. C., de Mulder, P. H., et al. (1999) · PubMed · Cited by 114 · see citing works
Radioimmunotherapy of B-cell non-Hodgkin's lymphoma: from clinical trials to clinical practice.
Juweid, M. E. (2002) · PubMed · Cited by 110 · see citing works
Targeted Therapy for Cancer
Wu, H., Chang, D.-K., & Huang, C.-T. (2006) · Cited by 118 · see citing works
Pretargeting radioimmunotherapy of a murine model of adult T-cell leukemia with the α-emitting radionuclide, bismuth 213
Zhang, M., Yao, Z., Garmestani, K., Axworthy, D. B., Zhang, Z., Mallett, R. W., Theodore, L. J., Goldman, C. K., Brechbiel, M. W., Carrasquillo, J. A., et al. (2002) · Blood · doi:10.1182/blood-2002-01-0107 · Cited by 103 · see citing works
Comparison of 90Y-Ibritumomab Tiuxetan and 131I-Tositumomab in Clinical Practice
Jacene, H. A., Filice, R. W., Kasecamp, W., & Wahl, R. L. (2007) · Journal of Nuclear Medicine · doi:10.2967/jnumed.107.043489 · Cited by 102 · see citing works
Self-citation
Rapid accumulation and internalization of radiolabeled herceptin in an inflammatory breast cancer xenograft with vasculogenic mimicry predicted by the contrast-enhanced dynamic MRI with the macromolecular contrast agent G6-(1B4M-Gd)(256).
Kobayashi, H., Shirakawa, K., Kawamoto, S., Saga, T., Sato, N., Hiraga, A., Watanabe, I., Heike, Y., Togashi, K., Konishi, J., et al. (2002) · PubMed · Cited by 99 · see citing works
A Phase I trial of 90Y-anti-carcinoembryonic antigen chimeric T84.66 radioimmunotherapy with 5-fluorouracil in patients with metastatic colorectal cancer.
Wong, J. Y. C., Shibata, S., Williams, L. E., et al. (2003) · PubMed · Cited by 97 · see citing works
Clinical applications of anti-CD20 antibodies
Gopal, A. K., & Press, O. W. (1999) · Journal of Laboratory and Clinical Medicine · doi:10.1016/s0022-2143(99)90164-6 · Cited by 96 · see citing works
Normal-Tissue Tolerance to Radiopharmaceutical Therapies, the Knowns and the Unknowns
Wahl, R. L., Sgouros, G., Iravani, A., Jacene, H., Pryma, D., Saboury, B., Capala, J., & Graves, S. A. (2021) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.262751 · Cited by 95 · see citing works
Self-citation
Low-dose, Fractionated Radioimmunotherapy for B-cell Malignancies using 131 I-LYM-1 Antibody
DeNardo, G. L., DeNardo, S. J., Lamborn, K. R., et al. (1998) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.1998.13.239 · Cited by 95 · see citing works
Pretargeting with the Affinity Enhancement System for Radioimmunotherapy
Barbet, J., Kraeber‐Bodéré, F., Vuillez, J., et al. (1999) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.1999.14.153 · Cited by 94 · see citing works
Radioimmunotherapy for B-cell lymphoma: Y90 ibritumomab tiuxetan and I131 tositumomab
Davies, A. J. (2007) · Oncogene · doi:10.1038/sj.onc.1210378 · Cited by 94 · see citing works
“This report updated previous efficacy reports (Kaminski et al., 1996; Wahl et al., 1998) of the initial phase I/II and included the first long-term follow-up data.”
BackgroundResult
Clinical radioimmunotherapy
Knox, S. J., & Meredith, R. F. (2000) · Seminars in Radiation Oncology · doi:10.1016/s1053-4296(00)80045-4 · Cited by 90 · see citing works
Antibody-based immunological therapies
Scott, A. M., & Welt, S. (1997) · Current Opinion in Immunology · doi:10.1016/s0952-7915(97)80054-4 · Cited by 89 · see citing works
High-Dose Radioimmunotherapy Combined with Fixed, Low-Dose Paclitaxel in Metastatic Prostate and Breast Cancer by Using a MUC-1 Monoclonal Antibody, m170, Linked to Indium-111/Yttrium-90 via a Cathepsin Cleavable Linker with Cyclosporine to Prevent Human Anti-mouse Antibody
Richman, C. M., DeNardo, S. J., OʼDonnell, R. T., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0211 · Cited by 87 · see citing works
Phase I therapy study of 186Re-labeled chimeric monoclonal antibody U36 in patients with squamous cell carcinoma of the head and neck.
Colnot, D. R., Quak, J. J., Roos, J. C., et al. (2000) · PubMed · Cited by 83 · see citing works
Targeted radionuclide therapy
Williams, L. E., DeNardo, G. L., & Meredith, R. F. (2008) · Medical Physics · doi:10.1118/1.2938520 · Cited by 80 · see citing works
Pretargeted radioimmunotherapy (PRIT™) for treatment of non-Hodgkin's lymphoma (NHL)
Weiden, P. L., & Breitz, H. B. (2001) · Critical Reviews in Oncology/Hematology · doi:10.1016/s1040-8428(01)00133-0 · Cited by 79 · see citing works
Red marrow dosimetry for radiolabeled antibodies that bind to marrow, bone, or blood components
Sgouros, G., Stabin, M. G., Erdi, Y. E., Akabani, G., Kwok, C., Brill, A. B., & Wessels, B. W. (2000) · Medical Physics · doi:10.1118/1.1288393 · Cited by 79 · see citing works
Effects of cytokines on CD20 antigen expression on tumor cells from patients with chronic lymphocytic leukemia
Venugopal, P., Sivaraman, S., Huang, X., et al. (2000) · Leukemia Research · doi:10.1016/s0145-2126(99)00206-4 · Cited by 77 · see citing works
“Studies are also in progress to increase the response rates to this therapy by (a) labeling it with toxins [19] or radioactive isotopes [20,21]; (b) combining it with chemotherapy [22,23]; and (c) combining it with bioactive agents such as interferon [24].”
Background
Bexxar®: Novel Radioimmunotherapy for the Treatment of Low-Grade and Transformed Low-Grade Non-Hodgkin's Lymphoma
Vose, J. M. (2004) · The Oncologist · doi:10.1634/theoncologist.9-2-160 · Cited by 76 · see citing works
Monoclonal antibody-based therapies for hematologic malignancies.
Multani, P. S., & Grossbard, M. L. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.11.3691 · Cited by 76 · see citing works
Characterization of scatter and penetration using Monte Carlo simulation in 131I imaging.
Dewaraja, Y. K., Ljungberg, M. H., & Koral, K. F. (2000) · PubMed · Cited by 75 · see citing works
Update on hybrid conjugate-view SPECT tumor dosimetry and response in 131I-tositumomab therapy of previously untreated lymphoma patients.
Koral, K. F., Dewaraja, Y. K., Li, J., Lin, Q., Regan, D. D., Zasadny, K. R., Rommelfanger, S. G., Francis, I. R., Kaminski, M. S., & Wahl, R. L. (2003) · PubMed · Cited by 75 · see citing works
Self-citation
Immunotherapy of non-Hodgkin's lymphoma with hLL2 (epratuzumab, an anti-CD22 monoclonal antibody) and Hu1D10 (apolizumab)
Leonard, J. P., & Link, B. K. (2002) · Seminars in Oncology · doi:10.1053/sonc.2002.30149 · Cited by 74 · see citing works
Radiobiology of radioimmunotherapy: Targeting CD20 B-cell antigen in non-Hodgkin's lymphoma
Hernandez, M. C., & Knox, S. J. (2004) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2004.02.065 · Cited by 74 · see citing works
Trials and tribulations: Oncological antibody imaging comes to the fore
Zuckier, L. S., & DeNardo, G. L. (1997) · Seminars in Nuclear Medicine · doi:10.1016/s0001-2998(97)80033-5 · Cited by 73 · see citing works
Rituximab: perspective on single agent experience, and future directions in combination trials
McLaughlin, P. J. (2001) · Critical Reviews in Oncology/Hematology · doi:10.1016/s1040-8428(01)00130-5 · Cited by 72 · see citing works
Yttrium 90 ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory low-grade non-Hodgkin's lymphoma
Gordon, L. I., Witzig, T. E., Wiseman, G., Flinn, I. W., Spies, S., Silverman, D. H. S., Emmanuolides, C., Cripe, L. D., Saleh, M. N., Czuczman, M. S., et al. (2002) · Seminars in Oncology · doi:10.1053/sonc.2002.30148 · Cited by 70 · see citing works
A re-examination of radioimmunotherapy in the treatment of non-Hodgkin lymphoma: prospects for dual-targeted antibody/radioantibody therapy
Sharkey, R. M., Press, O. W., & Goldenberg, D. M. (2009) · Blood · doi:10.1182/blood-2008-11-188896 · Cited by 71 · see citing works
“9 large amounts of unlabeled antibody, because high doses of the unlabeled antibody were therapeutically active on their own.(27) Thus, despite evidence that smaller doses of unlabeled”
Background
Identification of a human anti-CD55 single-chain Fv by subtractive panning of a phage library using tumor and nontumor cell lines.
Ridgway, J. B., Ng, E., Kern, J. A., et al. (1999) · PubMed · Cited by 71 · see citing works
Anti-Tumor Activity of K1-LysPE38QQR, an Immunotoxin Targeting Mesothelin, a Cell-Surface Antigen Overexpressed in Ovarian Cancer and Malignant Mesothelioma
Hassan, R., Viner, J. L., Wang, Q.-C., Margulies, I., Kreitman, R. J., & Pastan, I. H. (2000) · Journal of Immunotherapy · doi:10.1097/00002371-200007000-00011 · Cited by 70 · see citing works
“Thus they have been used as vehicles to carry chemotherapeutic agents (6), radioisotopes (7), and bacterial or plant toxins (8–10), so these agents can cause cell death on the specific binding of the monoclonal antibody to antigens on the surface of tumor cells.”
Background
Radioimmunotherapy: A Specific Treatment Protocol for Cancer by Cytotoxic Radioisotopes Conjugated to Antibodies
Kawashima, H. (2014) · The Scientific World JOURNAL · doi:10.1155/2014/492061 · Cited by 71 · see citing works
Anti-CD20-based therapy of B cell lymphoma: state of the art
Kosmas, C., Σταματόπουλος, Κ., Stavroyianni, N., Tsavaris, N. B., & Papadaki, T. (2002) · Leukemia · doi:10.1038/sj.leu.2402639 · Cited by 69 · see citing works
Comparison of immunoscintigraphy, efficacy, and toxicity of conventional and pretargeted radioimmunotherapy in CD20-expressing human lymphoma xenografts.
Subbiah, K., Hamlin, D. K., Pagel, J. M., Wilbur, D. S., Meyer, D. L., Axworthy, D. B., Mallett, R. W., Theodore, L. J., Stayton, P. S., & Press, O. W. (2003) · PubMed · Cited by 67 · see citing works
Monoclonal Antibodies in the Treatment of Malignancy: Basic Concepts and Recent Developments
Dillman, R. O. (2001) · Cancer Investigation · doi:10.1081/cnv-100107745 · Cited by 67 · see citing works
Therapy of B-cell lymphomas with monoclonal antibodies and radioimmunoconjugates: the Seattle experience
Johnson, T. A., & Press, O. W. (2000) · Annals of Hematology · doi:10.1007/s002770050576 · Cited by 64 · see citing works
“Kaminski has reported results from a phase-I trial administering non-myeloablative doses of I-131-anti-B1 (anti-CD20) mAb (34±161 mCi) to 34 patients with non-Hodgkin's lymphoma [32].”
Background
Treatment of relapsed B-cell non-Hodgkin's lymphoma with a combination of chimeric anti-CD20 monoclonal antibodies (rituximab) and G-CSF: final report on safety and efficacy
van der Kolk, L. E., Grillo-López, A. J., Baars, J. W., & van Oers, M. H. J. (2003) · Leukemia · doi:10.1038/sj.leu.2402995 · Cited by 64 · see citing works
Monoclonal Antibody Therapy in Lymphoid Malignancies
Hainsworth, J. D. (2000) · The Oncologist · doi:10.1634/theoncologist.5-5-376 · Cited by 63 · see citing works
Characterization of scFv-Ig Constructs Generated from the Anti-CD20 mAb 1F5 Using Linker Peptides of Varying Lengths
Shan, D., Press, O. W., Tsu, T. T., et al. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.162.11.6589 · Cited by 63 · see citing works
Gallium-67 scintigraphy: a cornerstone in functional imaging of lymphoma
Even‐Sapir, E., & Israel, O. (2003) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-003-1164-7 · Cited by 63 · see citing works
Rituximab in the treatment of diffuse large B-cell lymphomas
Coiffier, B. (2002) · Seminars in Oncology · doi:10.1053/sonc.2002.30153 · Cited by 63 · see citing works
Outpatient treatment with (131)I-anti-B1 antibody: radiation exposure to family members.
Rutar, F. J., AUGUSTINE, S., Colcher, D. M., et al. (2001) · PubMed · Cited by 61 · see citing works
In vitro characterization of 177Lu-radiolabelled chimeric anti-CD20 monoclonal antibody and a preliminary dosimetry study
Forrer, F., Chen, J., Fani, M., Powell, P., Lohri, A., Müller‐Brand, J., Moldenhauer, G., & Maëcke, H. R. (2009) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-009-1120-2 · Cited by 60 · see citing works
Non-Hodgkin's lymphomas: current classification and management
Skarin, A. T., & Dorfman, D. M. (1997) · CA A Cancer Journal for Clinicians · doi:10.3322/canjclin.47.6.351 · Cited by 60 · see citing works
A new era for radiolabeled antibodies in cancer?
DeNardo, S. J., Kroger, L. A., & DeNardo, G. L. (1999) · Current Opinion in Immunology · doi:10.1016/s0952-7915(99)00017-5 · Cited by 60 · see citing works
Update on Epidemiology and Therapeutics for Non-Hodgkin’s Lymphoma
Vose, J. M., Chiu, B. C. ‐., Cheson, B. D., Dancey, J. E., & Wright, J. (2002) · Hematology · doi:10.1182/asheducation-2002.1.241 · Cited by 58 · see citing works
Humanization and characterization of the anti-HLA-DR antibody 1D10
Kostelny, S. A., Link, B. K., Tso, J. Y., et al. (2001) · International Journal of Cancer · doi:10.1002/ijc.1366 · Cited by 58 · see citing works
125I-labeled anti-epidermal growth factor receptor-vIII single-chain Fv exhibits specific and high-level targeting of glioma xenografts.
Kuan, C., Reist, C. J., Foulon, C. F., et al. (1999) · PubMed · Cited by 57 · see citing works
Antibody-guided radiation therapy of cancer
Koppe, M. J., Postema, E. J., Aarts, F., et al. (2005) · Cancer and Metastasis Reviews · doi:10.1007/s10555-005-6195-z · Cited by 57 · see citing works
“The results indicated that the MTD could be doubled from 1 to 2 GBq/m2.”
BackgroundInfluential
Pretargeted Versus Directly Targeted Radioimmunotherapy Combined with Anti-CD20 Antibody Consolidation Therapy of Non-Hodgkin Lymphoma
Sharkey, R. M., Karacay, H., Johnson, C. R., Litwin, S., Rossi, E. A., McBride, W. J., Chang, C., & Goldenberg, D. M. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.058602 · Cited by 56 · see citing works
“, 135 and 635 mg), the specific biodistribution and targeting data from these patients were not presented in a manner to assess critically the benefit for the larger versus the smaller predose (28,29,39).”
Background
Clinical applications of newer radionuclide therapies
Brans, B. T., Lindén, O., Giammarile, F., Tennvall, J., & Punt, C. J. A. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2005.12.020 · Cited by 55 · see citing works
A practical methodology for patient release after tositumomab and (131)I-tositumomab therapy.
Siegel, J. A., Kroll, S., Regan, D. D., Kaminski, M. S., & Wahl, R. L. (2002) · PubMed · Cited by 55 · see citing works
Self-citation

Radioimmunotherapy with90Y-ibritumomab tiuxetan for a hemodialysis patient with relapsed follicular lymphoma
Fukuno, K., Tsurumi, H., Yamada, T., et al. (2013) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2013.783213 · Cited by 4 · see citing works
Ibritumomab tiuxetan for non-Hodgkin’s lymphoma
Johnston, P. B., Bondly, C., & Micallef, I. N. (2006) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.6.6.861 · Cited by 24 · see citing works
Ongoing Trials with Yttrium 90–Labeled Ibritumomab Tiuxetan in Patients with Non-Hodgkin's Lymphoma
Micallef, I. N. (2004) · Clinical Lymphoma · doi:10.3816/clm.2004.s.006 · Cited by 9 · see citing works
Current Concepts and Future Directions in Radioimmunotherapy
Lin, F. I., & Iagaru, A. H. (2010) · Current Drug Discovery Technologies · doi:10.2174/157016310793360684 · Cited by 15 · see citing works
Radioimmunotherapy for Non-Hodgkin Lymphoma : Historical Perspective and Current Status
Emmanouilides, C. E. (2007) · Journal of the Japan Society of the Reticuloendothelial System · doi:10.3960/jslrt.47.43 · Cited by 30 · see citing works

Authors: Kaminski, M. S., Zasadny, K. R., Francis, I. R., Fenner, M. C., Ross, C. W., Milik, A. W., Estes, J., Tuck, M., Regan, D., Fisher, S., Glenn, S. D., & Wahl, R. L.
Affiliations: University of Michigan (US)
ORCID: Kaminski, M S
Francis, I R
Tuck, M
Glenn, S D
Wahl, R L
Venue: Journal of Clinical Oncology
Publisher: American Society of Clinical Oncology (ASCO)
Published: 1996-07
Volume: 14
Issue: 7
Pages: 1974-1981
ISSN: 0732-183X (ISSN-L)
1527-7755
DOI: 10.1200/jco.1996.14.7.1974
OpenAlex: W1892026381
Cited by: 396
References: 0
Citations by year: 2024: 2 · 2023: 6 · 2022: 5 · 2021: 3 · 2020: 3 · 2019: 1 · 2018: 2 · 2017: 4 · 2016: 5 · 2015: 4 · 2014: 5 · 2013: 4 · 2012: 6
FWCI: 28.19
Type: journal article
Language: en
Open access: closed
Locations: Journal of Clinical Oncology (publishedVersion)
PubMed (publishedVersion)
Funders: National Institutes of Health (5r01ca056794-08, 5p01ca042768-03)
National Cancer Institute (R01-CA-56794, P0-1 CA42768)
National Center for Research Resources (M-01RR00042, M01RR000042)
Topics: Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiopharmaceutical Chemistry and Applications
Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Monoclonal and Polyclonal Antibodies Research
Keywords: iodine-131, anti-CD20 monoclonal antibody, radioimmunotherapy, B-cell lymphoma, treatment toxicity, hematologic toxicity, tumor targeting, tissue distribution, complete remission, relapsed/refractory lymphoma, indolent lymphoma, transformed lymphoma, chemotherapy-refractory disease
MeSH terms: Adult, Aged, Antibodies, Monoclonal, Dose-Response Relationship, Radiation, Female, Humans, Iodine Radioisotopes, Male, Middle Aged, Remission Induction, Lymphoma, B-Cell, Radioimmunotherapy, Antigens, CD20

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Cited by

Related

Record

About these checks